Compare MBINM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBINM | BRTX |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 735 | N/A |
| Industry | Major Banks | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 9.3M |
| IPO Year | N/A | 2015 |
| Metric | MBINM | BRTX |
|---|---|---|
| Price | $25.13 | $0.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.2K | ★ 6.4M |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.00 | $0.19 |
| 52 Week High | $25.96 | $2.10 |
| Indicator | MBINM | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 31.51 |
| Support Level | $24.81 | $0.19 |
| Resistance Level | $25.16 | $0.29 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 15.96 | 55.22 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.